Resverlogix value decimated by RVX-208 failure

22:50 EDT 27 Jun 2013 | SCRIP

Resverlogix lost nearly all of its value on 27 June when its stock sank 92.6% from $2.99 to $0.22 per share – dropping its market cap from $221.9 million to $16.4 million in one and a half hours of trading – after the Canadian company...

Original Article: Resverlogix value decimated by RVX-208 failure


More From BioPortfolio on "Resverlogix value decimated by RVX-208 failure"

Search BioPortfolio:

Relevant Topic

Prostate Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...


Searches Linking to this Story